Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 17 of 17 entries
View as:

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04655599 Org: User:
Start: 01/29/21 End: 04/13/21 Due: 04/13/22

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00619931 Org: User:
Start: 01/31/08 End: 06/30/08 Due: 06/30/09

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT04162769 Org: User:
Start: 10/04/19 End: 10/11/21 Due: 10/11/22

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT03945188 Org: User:
Start: 06/13/19 End: 02/16/22 Due: 02/16/23

Single-Dose Safety Study of APD791 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00529646 Org: User:
Start: 07/31/07 End: - Due: -

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Phase: N/A Priority: Normal
NCT ID: NCT03155932 Org: User:
Start: 12/29/17 End: 01/31/19 Due: 01/31/20

Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia

Phase: N/A Priority: Normal
NCT ID: NCT00664664 Org: User:
Start: 04/30/08 End: 11/30/08 Due: 11/30/09

Safety and Efficacy Study of APD125 in Patient With Insomnia

Phase: N/A Priority: Normal
NCT ID: NCT00452179 Org: User:
Start: 02/28/07 End: 06/30/07 Due: 06/30/08

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT02536404 Org: User:
Start: 01/25/16 End: 11/01/18 Due: 11/01/19

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

Phase: N/A Priority: Normal
NCT ID: NCT04043455 Org: User:
Start: 07/24/19 End: 04/29/21 Due: 04/29/22

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT02447302 Org: User:
Start: 10/15/15 End: 02/14/18 Due: 02/14/19

Single-dose Safety Study of APD916 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01093508 Org: User:
Start: 03/31/10 End: 07/31/10 Due: 07/31/11

Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Phase: N/A Priority: Normal
NCT ID: NCT03072953 Org: User:
Start: 06/07/17 End: 05/22/18 Due: 05/22/19

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Phase: N/A Priority: Normal
NCT ID: NCT03139032 Org: User:
Start: 07/17/17 End: 12/06/17 Due: 12/06/18

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT03996369 Org: User:
Start: 09/15/20 End: 12/07/21 Due: 12/07/22

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Phase: N/A Priority: Normal
NCT ID: NCT02044874 Org: User:
Start: 03/31/14 End: 11/30/14 Due: 11/30/15

Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

Phase: N/A Priority: Normal
NCT ID: NCT03155945 Org: User:
Start: 07/19/17 End: 09/10/18 Due: 09/10/19